{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:31:18Z","timestamp":1792189878611,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtha.2026.05.013","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:50:46Z","timestamp":1779259846000},"page":"3051-3062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-9005","authenticated-orcid":false,"given":"Isabelle","family":"Gouin-Thibault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-4732","authenticated-orcid":false,"given":"Corinne","family":"Frere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-3035","authenticated-orcid":false,"given":"Lana A.","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-582X","authenticated-orcid":false,"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-5697","authenticated-orcid":false,"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-4962","authenticated-orcid":false,"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3269-6156","authenticated-orcid":false,"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-6099","authenticated-orcid":false,"given":"Francois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Abdelhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Alberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseen M.","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Arachchillage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamrat Assefa","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Casais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Cesarman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thita","family":"Chiasakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Marc","family":"Samama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Tafur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vanasshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.05.013_bib1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtha.2025.02.012","article-title":"Results of an international survey on the management of therapeutic intensity unfractionated heparin: communication from the SSCs of the ISTH","volume":"23","author":"Gouin-Thibault","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib2","series-title":"Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays","first-page":"28","author":"Adcock","year":"2008"},{"key":"10.1016\/j.jtha.2026.05.013_bib3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/ijlh.13584","article-title":"International Council for Standardisation in Haematology (ICSH) recommendations for collection of blood samples for coagulation testing","volume":"43","author":"Kitchen","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/bjh.19729","article-title":"Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline","volume":"205","author":"Baker","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1515\/cclm-2020-0061","article-title":"The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)","volume":"59","author":"Cornes","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2019.10.019","article-title":"Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes","volume":"186","author":"Toulon","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.05.013_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12959-023-00465-8","article-title":"Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes","volume":"21","author":"Gremillet","year":"2023","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2026.05.013_bib8","doi-asserted-by":"crossref","first-page":"e297-","DOI":"10.1055\/a-2359-0987","article-title":"Management of therapeutic-intensity unfractionated heparin: a narrative review on critical points","volume":"8","author":"Gouin-Thibault","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2026.05.013_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1309\/AJCPE8CWKOVG4AGX","article-title":"Anticoagulation without monitoring","volume":"140","author":"Chandler","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2026.05.013_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.thromres.2017.08.003","article-title":"Impact of pneumatic tube system transport for the monitoring of heparin therapy","volume":"158","author":"Lebreton","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.05.013_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ijlh.13363","article-title":"Falsely decreased FVIII activity following pneumatic tube transport","volume":"43","author":"Wang","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/ijlh.13470","article-title":"Pneumatic tube transport of blood samples affects global hemostasis and platelet function assays","volume":"43","author":"Lorenzen","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.thromres.2018.08.024","article-title":"Alterations in the parameters of classic, global, and innovative assays of hemostasis caused by sample transportation via pneumatic tube system","volume":"170","author":"Poletaev","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.05.013_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1515\/cclm-2023-0632","article-title":"Diagnostic sample transport via pneumatic tube systems: data logger and their algorithms are sensitive to transport effects","volume":"62","author":"Ninnemann","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib15","first-page":"807","article-title":"Reference change values","volume":"50","author":"Fraser","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ijlh.13576","article-title":"The stability of \u2018add-on\u2019 coagulation assays in refrigerated citrated plasma stored on a packed cellular fraction","volume":"43","author":"Quirke","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/MBC.0b013e32835b72ea","article-title":"Sodium citrate vacuum tubes validation: preventing preanalytical variability in routine coagulation testing","volume":"24","author":"Lima-Oliveira","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.05.013_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0038-1646424","article-title":"An artefact related to the ratio of sample volume to the blood collection vial size which effects the APTTs of specimens taken to monitor heparin therapy","volume":"66","author":"Ray","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00001721-199310000-00020","article-title":"A low volume specimen container suitable for monitoring the aPTT of heparinized patients","volume":"4","author":"Ray","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.05.013_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0049-3848(83)90337-7","article-title":"Heparin inactivation during blood storage: its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole\u2014C.T.A.D. mixture","volume":"31","author":"Contant","year":"1983","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.05.013_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-0038-1651099","article-title":"Monitoring heparin therapy by the activated partial thromboplastin time\u2014the effect of pre-analytical conditions","volume":"57","author":"van den Besselaar","year":"1987","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib22","doi-asserted-by":"crossref","unstructured":"Savard P, Curis E, Gouin-Thibault I, Toussaint-Hacquard M, Delassasseigne C, Bauters A, Flaujac C, Eschw\u00e8ge V, Mouton C, Lecompte T, de Maistre E, Lasne D, Siguret V. Laboratory Monitoring of UFH in Different Settings (DEXHEP Study): association between Anti-Xa levels, platelet factor 4 (PF4) plasma levels and dextran sulfate. Thromb Haemost. In press. https:\/\/doi.org\/10.1055\/a-2749-6046","DOI":"10.1055\/a-2749-6046"},{"key":"10.1016\/j.jtha.2026.05.013_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11239-019-01882-1","article-title":"Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey?","volume":"48","author":"Billoir","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.05.013_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1055\/s-0043-1770096","article-title":"Factors influencing anti-Xa assays: a multicenter prospective study in critically ill and non-critically ill patients receiving unfractionated heparin","volume":"123","author":"Lasne","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1751-553X.2009.01172.x","article-title":"Photochemical decomposition of dipyridamole in aqueous solution and the utilization of citrate-theophylline-adenosine-dipyridamole anticoagulant for monitoring of heparin","volume":"32","author":"van den Besselaar","year":"2010","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/s-0032-1319770","article-title":"Unfractionated heparin for the treatment of venous thromboembolism: best practices and areas of uncertainty","volume":"38","author":"Cuker","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2017.07.006","article-title":"Should we abandon the APTT for monitoring unfractionated heparin?","volume":"157","author":"Arachchillage","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.05.013_bib28","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1515\/cclm-2020-0130","article-title":"Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data","volume":"58","author":"Hollestelle","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib29","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.05.013_bib30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17474086.2017.1345306","article-title":"Therapeutic monitoring of unfractionated heparin\u2014trials and tribulations","volume":"10","author":"Baluwala","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib31","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2011.11.016","article-title":"Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents","volume":"129","author":"Gouin-Thibaut","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.05.013_bib32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1160\/TH06-05-0290","article-title":"Monitoring unfractionated heparin with the aPTT: time for a fresh look","volume":"96","author":"Eikelboom","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1076029617741363","article-title":"Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms","volume":"24","author":"Whitman-Purves","year":"2018","journal-title":"Clin Appl Thromb"},{"key":"10.1016\/j.jtha.2026.05.013_bib34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1592\/phco.19.9.760.31547","article-title":"Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time","volume":"19","author":"Rosborough","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2026.05.013_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ijlh.14207","article-title":"Anti-factor Xa as the preferred assay to monitor heparin for the treatment of pulmonary embolism","volume":"46","author":"Zhu","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11239-015-1231-5","article-title":"Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations","volume":"41","author":"Vandiver","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.05.013_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1345\/aph.1Q161","article-title":"Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion","volume":"45","author":"Guervil","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2026.05.013_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1345\/aph.1R635","article-title":"Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin","volume":"47","author":"Price","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2026.05.013_bib40","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1111\/jth.14969","article-title":"Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents","volume":"18","author":"Smahi","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib41","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1055\/s-0038-1646008","article-title":"Modification of an amidolytic heparin assay to express protein-bound heparin and to correct for the effect of antithrombin III concentration","volume":"58","author":"Lyon","year":"1987","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102257","article-title":"Reassessment of dextran sulfate in anti-Xa assay for UFH laboratory monitoring","volume":"7","author":"Hardy","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib43","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/biomedicines9060700","article-title":"Optimization of heparin monitoring with anti-FXa assays and the impact of dextran sulfate for measuring all drug activity","volume":"9","author":"Amiral","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jtha.2026.05.013_bib44","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.thromres.2003.09.014","article-title":"Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine","volume":"111","author":"Mouton","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.05.013_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102196","article-title":"Heparin monitoring during extracorporeal membrane oxygenation: the effect of dextran sulfate on anti-Xa assay","volume":"7","author":"Hammami","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib46","first-page":"253","article-title":"Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations","volume":"43","author":"Marlar","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/ijlh.12918","article-title":"The importance of commutability in material used for quality control purposes","volume":"41","author":"Jennings","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.05.013_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120435","article-title":"Comparative study and relevant exploration on methods for establishing unfractionated heparin therapeutic range (HTR) based on APTT","volume":"577","author":"Chen","year":"2025","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jtha.2026.05.013_bib49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib75","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-119-2-199307150-00002","article-title":"Establishing a therapeutic range for heparin therapy","volume":"119","author":"Brill-Edwards","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1378\/chest.121.1.303","article-title":"The heparin anti-Xa therapeutic range: are we there yet?","volume":"121","author":"Smythe","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.05.013_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00001721-200011020-00004","article-title":"Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay","volume":"11","author":"Kitchen","year":"2000","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"10.1016\/j.jtha.2026.05.013_bib52","first-page":"55","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"13","author":"Byrne","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.05.013_bib53","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.05.013_bib54","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/eurheartj\/ehq330","article-title":"ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention","volume":"31","author":"Schulz","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.05.013_bib55","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/01.CIR.0000077530.53367.E9","article-title":"Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.05.013_bib56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejvs.2019.09.006","article-title":"Editor\u2019s choice\u2014European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia","volume":"59","author":"Bj\u00f6rck","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jtha.2026.05.013_bib57","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.05.013_bib58","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians Clinical Practice Guideline","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.05.013_bib59","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.05.013_bib60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FJC.0000000000001608","article-title":"Low-intensity heparin infusion compared with high-intensity heparin infusion dosing in patients with mechanical mitral valves: a retrospective cohort study","volume":"84","author":"Olsen","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jtha.2026.05.013_bib61","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.1997.00440430038005","article-title":"Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis","volume":"157","author":"Hull","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib62","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJM198610303151801","article-title":"Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis","volume":"315","author":"Hull","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib63","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based heparin dosing nomogram compared with a \u201cstandard care\u201d nomogram. A randomized controlled trial","volume":"119","author":"Raschke","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib64","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1001\/archinte.159.17.2029","article-title":"Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times","volume":"159","author":"Anand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2026.05.013_bib65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2146\/ajhp090123","article-title":"Weight-based heparin protocol using antifactor Xa monitoring","volume":"67","author":"Smith","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2026.05.013_bib66","article-title":"Improving safety of unfractionated heparin: a retrospective, quasi-experimental, observational study of the impact of a pocket card and a computerised prescription aid tool in the University Hospitals of Geneva","volume":"12","author":"Jimaja","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2026.05.013_bib67","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/ALN.0000000000004920","article-title":"Antithrombin levels and heparin responsiveness during veno-arterial extracorporeal membrane oxygenation: a prospective single-center cohort study","volume":"140","author":"Mansour","year":"2024","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jtha.2026.05.013_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.14648","article-title":"Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH","volume":"18","author":"Van Cott","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib69","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1160\/TH15-08-0687","article-title":"Antithrombin: anti-inflammatory properties and clinical applications","volume":"115","author":"Levy","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib70","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1309\/8E3U7RXEPXNP27R7","article-title":"Comparative performance of three anti\u2013factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin","volume":"126","author":"Lehman","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtha.2026.05.013_bib71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2019.01.007","article-title":"Monitoring of heparins in antithrombin-deficient patients","volume":"175","author":"Croles","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.05.013_bib72","article-title":"Laboratory response to unfractionated heparin at low antithrombin levels: an in-vitro study","volume":"8","author":"Gueret","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.05.013_bib73","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1213\/ANE.0b013e31827e4e62","article-title":"Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass","volume":"116","author":"Finley","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jtha.2026.05.013_bib74","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1213\/ANE.0000000000006314","article-title":"The rise and fall of antithrombin supplementation in cardiac surgery","volume":"136","author":"Ranucci","year":"2023","journal-title":"Anesth Analg"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626003363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626003363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:23:27Z","timestamp":1785885807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626003363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":75,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1538783626003363"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.05.013","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to monitor and manage unfractionated heparin in practice (Part 1)? Guidance from the SSC of the ISTH","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}